Business
Is Moderna stock a hold?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
A recent downgrade from buy to hold from a Wall Street analyst has Moderna (NASDAQ: MRNA) stock under pressure. Needham analyst Alan Carr has removed his $110 price target on the stock, citing valuation concerns.
Moderna’s market cap has swelled 885% this year to around $67 billion at recent prices. Despite coming under pressure recently, this is still one of the best performing large-cap healthcare stocks of 2020.
Following a meeting on 17 December with the Food and Drug Administration’s independent advisory committee, Moderna’s coronavirus vaccine candidate MRNA-1273 will probably become the second vaccine to earn an…
-
Noosa News22 hours agoMuster Dogs favourite Frank Finger makes final on-screen appearance with kelpie Annie in portrait show
-
General12 hours agoGoldfields man in coma after allegedly smashing head into ambulance windscreen
-
Business20 hours agoShould we be paying more attention to these two rocketing ASX small-cap mining stocks?
-
Noosa News22 hours agoWhy commuters are less likely to see familiar strangers on the bus, train or CityCat and why that makes us feel less safe